(Q40249402)

18 September 2017

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States (English)

1 reference

18 September 2017

1 reference

1 reference

1 reference

2

Poynard T

1 reference

18 September 2017

3

Sulkowski MS

1 reference

18 September 2017

Deuffic-Burban S

1

1 reference

PubMed ID

17244250

18 September 2017

Wong JB

series ordinal

4

1 reference

18 September 2017

1 February 2007

1 reference

Journal of Viral Hepatitis

18 September 2017

1 reference

18 September 2017

14

1 reference

18 September 2017

107-115

1 reference

18 September 2017

2

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

The burden of hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Empirically calibrated model of hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Prediction of hepatitis C burden in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Modeling the hepatitis C virus epidemic in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Comparing the public health burden of chronic hepatitis C and HIV infection in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

An Algorithm for Least-Squares Estimation of Nonlinear Parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

A Leisurely Look at the Bootstrap, the Jackknife, and Cross-Validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Minimum size of the acquired immunodeficiency syndrome (AIDS) epidemic in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Trends in HIV incidence among young adults in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

The completeness, validity, and timeliness of AIDS surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Hepatitis C in asymptomatic blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Reconstruction and future trends of the AIDS epidemic in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Different AIDS incubation periods and their impacts on reconstructing human immunodeficiency virus epidemics and projecting AIDS incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2006.00785.X

10.1111/J.1365-2893.2006.00785.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference

PubMed ID

17244250